<DOC>
	<DOC>NCT01498185</DOC>
	<brief_summary>To obtain safety and tolerability information in patients with type 1 diabetes where Dapagliflozin is added on to Insulin (for 14 days)</brief_summary>
	<brief_title>BMS - Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Dapagliflozin in Type 1 Diabetes</brief_title>
	<detailed_description>Study Classification : Safety, Pharmacokinetics and Pharmacodynamics</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<criteria>Type 1 diabetes with central lab Glycosylated hemoglobin (A1C) ≥ 7.0% and ≤ 10.0% Insulin use for at least 12 months and initiation immediately after diagnosis of diabetes Method of Insulin administration [multiple daily injections (MDI) or continuous subcutaneous Insulin infusion (CSII)] stable ≥ 3 months Stable basal Insulin dose ≥ 2 weeks Ages 18 to 65 years Central laboratory Cpeptide value of &lt; 0.7 ng/mL Body mass index (BMI) 18.5 to 35.0 kg/m2 History of type 2 diabetes mellitus (T2DM), maturity onset diabetes of young (MODY), pancreatic surgery or chronic pancreatitis Oral hypoglycemic agents History of diabetes ketoacidosis (DKA) within 24 weeks History of hospital admission for glycemic control within 6 months Frequent episodes of hypoglycemia (2 unexplained within 3 months) or hypoglycemic unawareness Aspartate aminotransferase (AST), Alanine aminotransferase (ALT) or Serum total bilirubin &gt; 2X Upper limit of normal (ULN) Abnormal Free T4 [if screening Thyroid Stimulating Hormone (TSH) abnormal] Estimated glomerular filtration rate (eGFR) Modification of Diet in Renal Disease (MDRD) formula ≤ 60 mL/min/1.73m2 Cardiovascular (CV)/Vascular Diseases within 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>